These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Value of mazindol in Gélineau's disease. Apropos of 10 cases]. Vespignani H; Weber M; Atlas P; Barroche G Rev Electroencephalogr Neurophysiol Clin; 1986 Oct; 16(3):317-22. PubMed ID: 3809694 [TBL] [Abstract][Full Text] [Related]
3. Mazindol in the treatment of narcolepsy. Parkes JD; Schachter M Acta Neurol Scand; 1979 Oct; 60(4):250-4. PubMed ID: 525256 [TBL] [Abstract][Full Text] [Related]
4. [Clinical use of mazindol in the treatment of essential obesity]. Guazzelli R; Piazzini M; Conti C; Papi L; Strazzulla G; Matassi L Clin Ter; 1987 Mar; 120(5):385-91. PubMed ID: 2953538 [No Abstract] [Full Text] [Related]
5. [Mazindol (AN-448): a new non-amphetamine anorectic in the treatment of exogenous obesity]. Delitala G; Alagna S; Masala A Clin Ter; 1977 Jun; 81(6):547-54. PubMed ID: 884939 [No Abstract] [Full Text] [Related]
6. Therapeutic effects of mazindol on narcolepsy. Iijima S; Sugita Y; Teshima Y; Hishikawa Y Sleep; 1986; 9(1 Pt 2):265-8. PubMed ID: 3704452 [TBL] [Abstract][Full Text] [Related]
7. Mazindol in the control of micturition. Woodhouse CR; Tiptaft RC Br J Urol; 1983 Dec; 55(6):636-8. PubMed ID: 6360295 [TBL] [Abstract][Full Text] [Related]
8. A multi-centre trial of mazindol ('Teronac') in general practice in Ireland. Evans ER; Wallace MG Curr Med Res Opin; 1975; 3(3):132-7. PubMed ID: 1149481 [TBL] [Abstract][Full Text] [Related]
10. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics. Bandisode MS; Boshell BR Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947 [No Abstract] [Full Text] [Related]
11. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)]. Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827 [No Abstract] [Full Text] [Related]
12. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222 [TBL] [Abstract][Full Text] [Related]
13. Mazindol: its efficacy and mode of action in generating weight loss. Johnson WG; Hughes JR Addict Behav; 1979; 4(3):237-44. PubMed ID: 495247 [No Abstract] [Full Text] [Related]
14. [Mazindol: a new anorectic drug]. Siani V Clin Ter; 1978 Jan; 84(1):100-1. PubMed ID: 630811 [No Abstract] [Full Text] [Related]
15. AN 448 Sandoz (Mazindol) in the treatment of obesity. Wallace AG Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265 [TBL] [Abstract][Full Text] [Related]
16. The effect of an anorectic agent (Mazindol) on control of obese diabetics. Sanders M; Breidahl H Med J Aust; 1976 Oct; 2(15):576-7. PubMed ID: 994969 [TBL] [Abstract][Full Text] [Related]
17. Mazindol (Teronac)- another anorectic drug. Drug Ther Bull; 1974 Dec; 12(26):101-2. PubMed ID: 4459058 [No Abstract] [Full Text] [Related]
18. [Overweight as a therapeutic problem. Experience with the appetite depressant Mazindol]. Linke H Med Welt; 1976 Oct; 27(42):2021-5. PubMed ID: 792620 [No Abstract] [Full Text] [Related]
19. A double-blind trial of mazindol using a very low calorie formula diet. Baird IM; Howard AN Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631 [TBL] [Abstract][Full Text] [Related]
20. [Mazindol (Teronac) in the treatment of predominant by food-dependent obesity]. Husmann F Med Welt; 1976 Oct; 27(40):1904-8. PubMed ID: 790077 [No Abstract] [Full Text] [Related] [Next] [New Search]